STOCK TITAN

Curis (CRIS) CEO converts Series B preferred stock into common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Curis Inc. reported that President & CEO James E. Dentzer converted preferred shares into common stock. On March 20, 2026, he converted 100 shares of Series B Convertible Non-Redeemable Preferred Stock into 133,333 shares of common stock for no additional consideration through an automatic conversion.

After the conversion, Dentzer directly owned 148,730 shares of Curis common stock. Each Series B preferred share converted into 1,333.33 common shares, consistent with the terms described in the related certificate of designations and subject to specified beneficial ownership limitations.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dentzer James E

(Last)(First)(Middle)
128 SPRING STREET
BUILDING C - SUITE 500

(Street)
LEXINGTON MASSACHUSETTS 02421

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CURIS INC [ CRIS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/20/2026C133,333A(1)148,730D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series B Convertible Preferred Stock(1)03/20/2026C100 (1) (1)Common Stock133,333(1)0D
Explanation of Responses:
1. Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.
Remarks:
/s/ Diantha Duvall, Attorney-in-fact03/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Curis (CRIS) report for James E. Dentzer?

Curis reported that President & CEO James E. Dentzer converted 100 shares of Series B Convertible Preferred Stock into 133,333 shares of common stock. This was recorded as a derivative conversion and not as an open-market purchase or sale of Curis shares.

How many Curis (CRIS) common shares does James E. Dentzer hold after this Form 4?

After the reported conversion, James E. Dentzer directly owns 148,730 shares of Curis common stock. This reflects the addition of 133,333 common shares received from converting 100 shares of Series B Convertible Non-Redeemable Preferred Stock at the stated 1,333.33-to-1 conversion ratio.

Was cash paid in the Curis (CRIS) insider conversion on March 20, 2026?

No new cash was paid in this transaction. The 100 Series B preferred shares automatically converted into 133,333 common shares for no additional consideration, in line with the certificate of designations and the applicable beneficial ownership limitations governing the preferred stock.

What is the conversion rate of Curis (CRIS) Series B Convertible Preferred Stock?

Each share of Curis Series B Convertible Non-Redeemable Preferred Stock converts into 1,333.33 shares of common stock. This rate is specified in the certificate of designations that governs the Series B preferred shares and applied to the March 20, 2026 automatic conversion.

How is the Curis (CRIS) insider transaction classified on the Form 4?

The transaction is classified as a derivative conversion with code “C,” indicating conversion of a derivative security. Internally it is labeled as an acquisition direction, reflecting that the reporting person received additional common shares through conversion rather than through an open-market buy transaction.
Curis

NASDAQ:CRIS

View CRIS Stock Overview

CRIS Rankings

CRIS Latest News

CRIS Latest SEC Filings

CRIS Stock Data

10.59M
12.79M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
LEXINGTON